Achieving Effective Hematological Oncology Clinical Trials

This free webinar examines the nuances of successfully conducting hematological oncology clinical trials.

Hematological malignancies such as leukemia, multiple myeloma and lymphoma represent a subset of indications within oncology that are wholly different from solid tumors. The growing hematological oncology therapy market is fueling both large numbers of clinical studies and, more importantly, an enhanced and refined understanding of cancer pathologies. Conducting clinical trials in hematological malignancies requires an understanding of a rapidly evolving treatment paradigm that is increasingly nuanced, complex and patient-directed. Companies developing hematological oncology therapies must capitalize on the principles and infrastructures shared by solid tumor oncology trials while adapting endpoints, study designs and data management approaches as well as considering patients’ experiences to address the particular challenges related to investigating candidate treatments for blood-based cancers.

Join this webinar to gain an understanding of critical differences between solid tumor and hematological oncology and a discussion on the nuances of conducting successful hematological oncology clinical trials.

Learning Objectives

• Understand critical trial design considerations; including tumor type, standard of care vs. research interests, and overall data capture nuances
• Learn how to create meaningful, measurable endpoints and how they differ from solid tumor oncology studies
• Recognize how to effectively monitor and manage data and queries within hematology oncology studies
• Gain insight into selecting ideal trial sites for rare hematological malignancies and the importance of working with an oncology-experienced team

Speakers

Ray Reilly, Senior Director, Oncology Division, Novella Clinical

Ray Reilly has a combined 21 years in clinical research and is responsible for driving strategy and overseeing operations for Novella’s Oncology Division. He has managed many oncology programs and individual protocols including both early and late phase, domestic and international in scope. He possesses extensive knowledge of clinical research processes, project management methodology, regulations and guidelines. Ray’s experience spans site level work, academia, pharma and clinical research environments, with the last five years focused specifically on hematologic malignancies. During his ten year tenure with Novella, he has been involved in ensuring continued excellence within the company during significant corporate growth and has had involvement within clinical monitoring, regulatory/QA, clinical training and project management.

Message Presenter

Richard Gams, MD, Chief Scientific Officer, Novella Clinical

Dr. Richard Gams is a board-certified hematologist/oncologist with more than 40 years’ clinical research experience. As Novella’s chief scientific officer, he guides training, protocol design, medical monitoring and pharmcovigilance, and is focused primarily on hematologic malignancies including leukemias, lymphomas, myelodysplasia and multiple myeloma. Prior to joining Novella, he played an instrumental role at Adria Laboratories (now part of Pfizer) in moving three breast cancer drugs and a therapy for acute myelogenous leukemia to FDA approval and commercialization in the 1990s, and later founded Prologue Research International, a contract research organization. Dr. Gams served as a Professor of Medicine in the Division of Hematology/Oncology at the University of Alabama at Birmingham and Chairman of the Lymphoma Committee of the Southeastern Cancer Study Group. Additionally, he was Professor of Medicine in Hematology/Oncology and Director, Developmental Therapeutics for the Comprehensive Cancer Center (CCC) at The Ohio State University.

Message Presenter